Regenerx Biopharm In
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceu… Read more
Regenerx Biopharm In - Asset Resilience Ratio
Regenerx Biopharm In (RGRX) has an Asset Resilience Ratio of 53.12% as of December 2007. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2007)
This chart shows how Regenerx Biopharm In's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Regenerx Biopharm In's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.58 Million | 53.12% |
| Total Liquid Assets | $4.58 Million | 53.12% |
Asset Resilience Insights
- Very High Liquidity: Regenerx Biopharm In maintains exceptional liquid asset reserves at 53.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Regenerx Biopharm In Industry Peers by Asset Resilience Ratio
Compare Regenerx Biopharm In's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Regenerx Biopharm In (2005–2007)
The table below shows the annual Asset Resilience Ratio data for Regenerx Biopharm In.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2007-12-31 | 53.12% | $4.58 Million | $8.62 Million | +30.27pp |
| 2006-12-31 | 22.85% | $4.00 Million | $17.50 Million | -11.83pp |
| 2005-12-31 | 34.68% | $2.68 Million | $7.72 Million | -- |